Home > Research > Publications & Outputs > Using a dose-finding benchmark to quantify the ...

Links

Text available via DOI:

View graph of relations

Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies. / Mozgunov, P.; Jaki, T.; Paoletti, X.

In: Biometrical Journal, Vol. 62, No. 7, 01.11.2020, p. 1717-1729.

Research output: Contribution to journalJournal articlepeer-review

Harvard

APA

Vancouver

Author

Mozgunov, P. ; Jaki, T. ; Paoletti, X. / Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies. In: Biometrical Journal. 2020 ; Vol. 62, No. 7. pp. 1717-1729.

Bibtex

@article{c24d81c387f047f59c74b636b411ba9d,
title = "Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies",
abstract = "While there is recognition that more informative clinical endpoints can support better decision-making in clinical trials, it remains a common practice to categorize endpoints originally measured on a continuous scale. The primary motivation for this categorization (and most commonly dichotomization) is the simplicity of the analysis. There is, however, a long argument that this simplicity can come at a high cost. Specifically, larger sample sizes are needed to achieve the same level of accuracy when using a dichotomized outcome instead of the original continuous endpoint. The degree of “loss of information” has been studied in the contexts of parallel-group designs and two-stage Phase II trials. Limited attention, however, has been given to the quantification of the associated losses in dose-ranging trials. In this work, we propose an approach to estimate the associated losses in Phase II dose-ranging trials that is free of the actual dose-ranging design used and depends on the clinical setting only. The approach uses the notion of a nonparametric optimal benchmark for dose-finding trials, an evaluation tool that facilitates the assessment of a dose-finding design by providing an upper bound on its performance under a given scenario in terms of the probability of the target dose selection. After demonstrating how the benchmark can be applied to Phase II dose-ranging trials, we use it to quantify the dichotomization losses. Using parameters from real clinical trials in various therapeutic areas, it is found that the ratio of sample sizes needed to obtain the same precision using continuous and binary (dichotomized) endpoints varies between 70% and 75% under the majority of scenarios but can drop to 50% in some cases. {\textcopyright} 2020 The Authors. Biometrical Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.",
keywords = "continuous endpoint, dichotomization, dose-ranging trials, nonparametric optimal benchmark, phase II",
author = "P. Mozgunov and T. Jaki and X. Paoletti",
year = "2020",
month = nov,
day = "1",
doi = "10.1002/bimj.201900332",
language = "English",
volume = "62",
pages = "1717--1729",
journal = "Biometrical Journal",
issn = "0323-3847",
publisher = "Wiley-VCH Verlag",
number = "7",

}

RIS

TY - JOUR

T1 - Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies

AU - Mozgunov, P.

AU - Jaki, T.

AU - Paoletti, X.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - While there is recognition that more informative clinical endpoints can support better decision-making in clinical trials, it remains a common practice to categorize endpoints originally measured on a continuous scale. The primary motivation for this categorization (and most commonly dichotomization) is the simplicity of the analysis. There is, however, a long argument that this simplicity can come at a high cost. Specifically, larger sample sizes are needed to achieve the same level of accuracy when using a dichotomized outcome instead of the original continuous endpoint. The degree of “loss of information” has been studied in the contexts of parallel-group designs and two-stage Phase II trials. Limited attention, however, has been given to the quantification of the associated losses in dose-ranging trials. In this work, we propose an approach to estimate the associated losses in Phase II dose-ranging trials that is free of the actual dose-ranging design used and depends on the clinical setting only. The approach uses the notion of a nonparametric optimal benchmark for dose-finding trials, an evaluation tool that facilitates the assessment of a dose-finding design by providing an upper bound on its performance under a given scenario in terms of the probability of the target dose selection. After demonstrating how the benchmark can be applied to Phase II dose-ranging trials, we use it to quantify the dichotomization losses. Using parameters from real clinical trials in various therapeutic areas, it is found that the ratio of sample sizes needed to obtain the same precision using continuous and binary (dichotomized) endpoints varies between 70% and 75% under the majority of scenarios but can drop to 50% in some cases. © 2020 The Authors. Biometrical Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

AB - While there is recognition that more informative clinical endpoints can support better decision-making in clinical trials, it remains a common practice to categorize endpoints originally measured on a continuous scale. The primary motivation for this categorization (and most commonly dichotomization) is the simplicity of the analysis. There is, however, a long argument that this simplicity can come at a high cost. Specifically, larger sample sizes are needed to achieve the same level of accuracy when using a dichotomized outcome instead of the original continuous endpoint. The degree of “loss of information” has been studied in the contexts of parallel-group designs and two-stage Phase II trials. Limited attention, however, has been given to the quantification of the associated losses in dose-ranging trials. In this work, we propose an approach to estimate the associated losses in Phase II dose-ranging trials that is free of the actual dose-ranging design used and depends on the clinical setting only. The approach uses the notion of a nonparametric optimal benchmark for dose-finding trials, an evaluation tool that facilitates the assessment of a dose-finding design by providing an upper bound on its performance under a given scenario in terms of the probability of the target dose selection. After demonstrating how the benchmark can be applied to Phase II dose-ranging trials, we use it to quantify the dichotomization losses. Using parameters from real clinical trials in various therapeutic areas, it is found that the ratio of sample sizes needed to obtain the same precision using continuous and binary (dichotomized) endpoints varies between 70% and 75% under the majority of scenarios but can drop to 50% in some cases. © 2020 The Authors. Biometrical Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

KW - continuous endpoint

KW - dichotomization

KW - dose-ranging trials

KW - nonparametric optimal benchmark

KW - phase II

U2 - 10.1002/bimj.201900332

DO - 10.1002/bimj.201900332

M3 - Journal article

VL - 62

SP - 1717

EP - 1729

JO - Biometrical Journal

JF - Biometrical Journal

SN - 0323-3847

IS - 7

ER -